RE:Whats the Stock Projections for RVXDeoends on how large the upfront payment is and how many of RVX's planned trials it will fund.
If it's over $100mm, share price could appreciate considerable (>$6).
If less, I agree with Narmac seeing $4-5 by end of year. Royalties amount will also play a part. Don stated that if results are so-so but FDA approval is still granted, the partner "isn't paying that much" so there's a decent chance market could de disappointed by the royalties section of the deal.